Table 3 Adverse events during the second year of the study
Combination therapy groupMonotherapy groupp Value
>30% increase in creatinine vs baseline11 (14)2 (4)0.046
Hypertrichosis7 (10)4 (6)0.53
Dyspepsia7 (10)7 (10)1
Sleeplessness2 (3)7 (10)0.17
>10% decrease in serum albumin vs baseline3 (4)9 (13)0.13
  • Number (%) of adverse events that occurred in >10% of patients in either treatment group. p Values were determined by Fisher exact test.